CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 258 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Rosuvastatin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00395486
NCT00395486Phase 4Completed
CompareCT.gov

A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C

AstraZeneca·interventional·Posted Nov 3, 2006·Updated Jul 11, 2011

In Brief

A Phase 4 clinical trial evaluating Rosuvastatin and Atorvastatin for Metabolic Syndrome X. Completed, enrolled 258 participants across 3 sites.

Detailed Summary

The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome X
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2006
Enrollment StartSep 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.7 years ago

Interventions

Rosuvastatindrug

10mg

Atorvastatindrug

10mg